Acne Vulgaris, Polyendocrine Metabolic Ovarian Syndrome
Conditions
Keywords
Polyendocrine metabolic ovarian syndrome, Acne vulgaris, PMOS
Brief summary
The aim of this study is to determine the prevalence of polyendocrine metabolic ovarian syndrome (PMOS) among female patients diagnosed with acne vulgaris in Sohag university hospital
Detailed description
A cross-sectional observational study designed to determine the prevalence of polycystic ovary syndrome (PCOS) among patients diagnosed with acne vulgaris attending Sohag University Hospital.
Interventions
None listed
Sponsors
Sohag University
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
15 Years to 49 Years
Healthy volunteers
No
Inclusion criteria
* Female patients at childbearing age ( 15 - 49 years) (World Health, 2024). * Patients clinically diagnosed with acne vulgaris. • Clinical diagnosis of Acne vulgaris: o Presence of comedones (open/black and closed/white), inflammatory lesions (papules, pustules, or nodules), with or without post-acne changes such as hyperpigmentation or scarring (Oge et al., 2019). * Patients diagnosed with polyendocrine metabolic ovarian syndrome (PMOS) according to the 2023 International Evidence-based Guideline for PCOS diagnosis. * Diagnostic criteria for PMOS diagnosis in adults : (Forslund et al., 2024). * Diagnosis of PMOS will be based on the presence of at least two of the following three criteria after exclusion of other etiologies: 1\. Ovulatory dysfunction: * Irregular menstrual cycles or oligo/anovulation. 2. Clinical and/or biochemical hyperandrogenism: * Clinical signs such as hirsutism and/or acne, or biochemical evidence of elevated androgen levels. 3\. Polycystic ovarian morphology (PCOM): * Polycystic ovaries detected by pelvic ultrasound, or elevated anti-Müllerian hormone (AMH) level in adults as an alternative to ultrasound. * Most women with PMOS have a combination of hyperandrogenism and irregular cycles, and in these cases there is no need to assess PCOM. In adolescents, both ovulatory dysfunction and hyperandrogenism are mandatory (Forslund et al., 2024). * Patients willing to participate and provide informed consent.
Exclusion criteria
* Pregnant women. * Lactating mothers * Women diagnosed with other acneiform lesions * Women on certain drug treatments like oral contraceptive pills, ovarian stimulating drugs and oral hypoglycemic agents like metformin. * Patients with incomplete clinical data or who refuse to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of polyendocrine metabolic ovarian syndrome (PMOS) among patients diagnosed with acne vulgaris in Sohag university hospital | Over 1 year |
Countries
Egypt
Contacts
CONTACTOmar Shazly Saleh, Resident
Outcome results
None listed